U.S. FDA considering lowering recommended age for Pfizer/BioNTech COVID-19 boosters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
FILE PHOTO: A nurses fills up syringes for patients as they receive their coronavirus disease (COVID-19) booster vaccination during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin
NEW YORK (Reuters) - A top U.S. Food and Drug Administration official said on Friday that the agency is considering lowering the recommended age for who should receive booster shots of the Pfizer/BioNTech COVID-19 vaccine to as young as 40 years old, based on data from Israel suggesting the vaccine's efficacy is waning.
Israeli scientists presented "data that seemed compelling in the 40 and up age range," Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research said, speaking to the agency's Vaccines and Related Biological Products Advisory Committee.
(Reporting by Michael Erman, Editing by Franklin Paul)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BP, Louisiana agree to Deepwater Horizon settlement payout, resolve coastal cases
- Actinium to present ATNM-400 prostate cancer trial data at ESMO 2026
- BeOne cancer drug combo shows 27-month median OS in gastric trial
Create E-mail Alert Related Categories
FDA, General News, ReutersRelated Entities
AdCom, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
